RT Journal Article SR Electronic T1 Development and validation of personalised risk prediction models for early detection and diagnosis of primary liver cancer among the English primary care population using the QResearch® database: research protocol and statistical analysis plan JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2022.01.24.22269755 DO 10.1101/2022.01.24.22269755 A1 Liao, Weiqi A1 Jepsen, Peter A1 Coupland, Carol A1 Innes, Hamish A1 Matthews, Philippa C. A1 Campbell, Cori A1 Barnes, Eleanor A1 Hippisley-Cox, Julia A1 , YR 2022 UL http://medrxiv.org/content/early/2022/01/25/2022.01.24.22269755.abstract AB Background and research aim The incidence and mortality of liver cancer have been increasing in recent years in the UK. However, liver cancer is still under-studied. The Early Detection of Hepatocellular Liver Cancer (DeLIVER-QResearch) project aims to address the research gap and generate new knowledge to improve early detection and diagnosis of primary liver cancer from general practice and at the population level. There are three research objectives: (1) to understand the current epidemiology of primary liver cancer in England, (2) to identify and quantify the symptoms and comorbidities associated with liver cancer, and (3) to develop and validate prediction models for early detection of liver cancer suitable for implementation in clinical settings.Methods This population-based study uses the QResearch® database (version 46) and includes patients aged 25-84 years old and without a diagnosis of liver cancer at the cohort entry (study period: 1 January 2008 to 31 December 2020). The team conducted a literature review (with additional clinical input) to inform the inclusion of variables for data extraction from the QResearch database. A wide range of statistical techniques will be used for the three research objectives, including descriptive statistics, multiple imputation for missing data, conditional logistic regression to investigate the association between the clinical features (symptoms and comorbidities) and the outcome, fractional polynomial terms to explore the non-linear relationship between continuous variables and the outcome, and Cox regression for the prediction model. We have a specific focus on the 1-year, 5-year, and 10-year absolute risks of developing liver cancer, as risks at different time points have different clinical implications. The internal-external validation approach will be used, and the discrimination and calibration of the prediction model will be evaluated.Discussion The DeLIVER-QResearch project uses large-scale representative population-based data to address the most relevant research questions for early detection and diagnosis of primary liver cancer in England. This project has great potential to inform the national cancer strategic plan and yield substantial public and societal benefits.Medical Subject Headings (MeSH) Liver Neoplasms; Carcinoma, Hepatocellular; Cholangiocarcinoma; Clinical Decision Rules; Early Detection of Cancer; Early Diagnosis; Symptom Assessment; ComorbidityCompeting Interest StatementJH-C is an unpaid director of QResearch, a not-for-profit organisation in a partnership between the University of Oxford and EMIS Health, who supply the QResearch database for this work. JH-C is a founder and shareholder of ClinRisk Ltd and was its medical director until 31 May 2019. ClinRisk Ltd produces open and closed source software to implement clinical risk algorithms into clinical computer systems including the original QCancer algorithms referred to above. Other authors have no interests to declare for this submitted work.Funding StatementThe Early Detection of Hepatocellular Liver Cancer (DeLIVER) project is funded by Cancer Research UK (Early Detection Programme Award, grant reference: C30358/A29725). QResearch received funding from the NIHR Biomedical Research Centre, Oxford, grants from John Fell Oxford University Press Research Fund, grants from Cancer Research UK (Grant number C5255/A18085) through the Cancer Research UK Oxford Centre, grants from the Oxford Wellcome Institutional Strategic Support Fund (204826/Z/16/Z). EB acknowledges the support of the NIHR as an NIHR Senior Investigator. The views expressed in this manuscript are those of the authors and not the NIHR or NHS. PCM is supported by a Wellcome Trust intermediate clinical fellowship (Ref. 110110/Z/15/Z). This research is funded in whole, or in part, by the Wellcome Trust. For the purpose of Open Access, the author has applied a CC BY public copyright licence to any author accepted manuscript version arising from this submission.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study has been approved by the QResearch Scientific Committee on 8 July 2021. QResearch is a Research Ethics Approved Research Database, confirmed from the East Midlands Derby Research Ethics Committee (research ethics reference: 18/EM/0400, project reference: OX30 DeLIVER).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesConsidering the sensitive nature of anonymised patient-level data and to meet the requirement of the data provider, the data will be only accessible to the named researchers of the team.